NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Comparative Clinical and Cost-Effectiveness of Drug Therapies for Relapsing-Remitting Multiple Sclerosis [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2013 Oct. (CADTH Therapeutic Review, No. 1.2B.)

Cover of Comparative Clinical and Cost-Effectiveness of Drug Therapies for Relapsing-Remitting Multiple Sclerosis

Comparative Clinical and Cost-Effectiveness of Drug Therapies for Relapsing-Remitting Multiple Sclerosis [Internet].

Show details

APPENDIX 13DETAILED DATA OF MONOTHERAPY TRIALS

Table A13.1. Data for Relapse – Annualized Relapse Rate (PDF, 221K)

Table A13.2. Data for Relapse – Patients With Relapse-Free (PDF, 149K)

Table A13.3. Data for Disability – Patients With Disability Progression (PDF, 138K)

Table A13.4. Data for Disability – Mean Change EDSS From Baseline (PDF, 123K)

Table A13.5. Data for Disability – Mean Change MSFC From Baseline (PDF, 100K)

Table A13.6. Data for MRI – Patients With Gadolinium-Enhancing Lesions (PDF, 119K)

Table A13.7. Data for MRI – Mean Number of Gadolinium-Enhancing Lesions (PDF, 125K)

Table A13.8. Data for MRI – Patients With New or Enlarging T2-hyperintense Lesions (PDF, 115K)

Table A13.9. Data for MRI – Mean Number of New or Enlarging T2-hyperintense Lesions (PDF, 124K)

Table A13.10. Data for Safety – Death (PDF, 131K)

Table A13.11. Data for Safety – Serious Adverse Events (PDF, 129K)

Table A13.12. Data for Safety – Treatment Discontinuation Due to Adverse Events (PDF, 145K)

Table A13.13. Data for Safety – Total Withdrawal (PDF, 153K)

Table A13.14. Data for Safety – Influenza-Like Symptoms (PDF, 123K)

Table A13.15. Data for Safety – Fatigue (PDF, 119K)

Table A13.16. Data for Safety – Flushing (PDF, 99K)

Table A13.17. Data for Safety – Infection (PDF, 125K)

Table A13.18. Data for Safety – Depression (PDF, 123K)

Table A13.19. Data for Safety – Infusion Reactions (PDF, 98K)

Table A13.20. Data for Safety – Injection Site Reactions (PDF, 122K)

Table A13.21. Data for Safety – Hypersensitivity (PDF, 103K)

Table A13.22. Data for Safety – Skin Disorders (PDF, 105K)

Table A13.23. Data for Safety – Cancer (PDF, 110K)

Table A13.24. Data for Safety – Liver Enzyme Elevation (PDF, 127K)

Table A13.25. Data for Safety – Thyroid Disorders (PDF, 99K)

Table A13.26. Data for Safety – Gastrointestinal Disorders (PDF, 112K)

Table A13.27. Data for Safety – Antibodies (PDF, 111K)

Table A13.28. Data for Safety – Cardiovascular Disorders (Bradycardia and Atrioventricular Block) (PDF, 99K)

Table A13.29. Relapse-Related Data of Included Studies (PDF, 110K)

Copyright © CADTH March 2013.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK169766

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (9.8M)

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...